GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

telitacicept   Click here for help

GtoPdb Ligand ID: 11827

Synonyms: RC-18 | RC18 | Tai'ai®
Approved drug Immunopharmacology Ligand
telitacicept is an approved drug (China (2021))
Compound class: Peptide
Comment: Telitacicept (RC18) is a recombinant fusion protein that combines the ligand-binding domain of the TACI receptor and the Fc component of human IgG. It was designed to inhibit the signalling of B cell BAFF (a.k.a. BLyS; TNFSF13B) and APRIL (TNFSF13) as a disease-modifying mechainism for the treatment of B cell-mediated autoimmune diseases [2-4,6].
Peptide Sequence Click here for help
SRVDQEERFPQGLWTGVAMRSCPEEQYWDPLLGTCMSCKTICNHQSQRTCAAFCRSLSCRKEQGKFYDHLLRDCISCASI
CGQHPKQCAYFCENKLRSPVNLPPELDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPS
RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
HYTQKSLSLSPGK
Chemical Modification
Disulfide bridges locations:
intra-TACI: 22-35, 38-50, 42-54, 59-74, 77-88, 81-92
intra-IgG1 Fc: 147-207, 253-311
inter-IgG1 Fc: 112-112', 115-115'
Glycosylation sites: Asn183, Asn183'